Search

Your search keyword '"Gragnano, Felice"' showing total 4 results
Start Over Author "Gragnano, Felice" Journal circulation
4 results on '"Gragnano, Felice"'

1. Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease

Author

Calabrò, Paolo, Gragnano, Felice, Niccoli, Giampaolo, Marcucci, Rossella, Zimarino, Marco, Spaccarotella, Carmen, Renda, Giulia, Patti, Giuseppe, Andò, Giuseppe, Moscarella, Elisabetta, Mancone, Massimo, Cesaro, Arturo, Giustino, Gennaro, De Caterina, Raffaele, Mehran, Roxana, Capodanno, Davide, Valgimigli, Marco, Windecker, Stephan, Dangas, George D., Indolfi, Ciro, and Angiolillo, Dominick J.

Published
2021
Full Text
View/download PDF

2. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment–Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial

Author

Gargiulo, Giuseppe, Esposito, Giovanni, Avvedimento, Marisa, Nagler, Michael, Minuz, Pietro, Campo, Gianluca, Gragnano, Felice, Manavifar, Negar, Piccolo, Raffaele, Tebaldi, Matteo, Cirillo, Plinio, Hunziker, Lukas, Vranckx, Pascal, Leonardi, Sergio, Heg, Dik, Windecker, Stephan, and Valgimigli, Marco

Published
2020
Full Text
View/download PDF

4. Letter by Calabrò et al Regarding Article, 'Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)'

Author

Arturo Cesaro, Paolo Calabrò, Felice Gragnano, Calabrò, Paolo, Gragnano, Felice, and Cesaro, Arturo

Subjects
medicine.medical_specialty, Arterial disease, Disease, 030204 cardiovascular system & hematology, Antibodies, Monoclonal, Humanized, Peripheral Arterial Disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Physiology (medical), Internal medicine, Outcome Assessment, Health Care, medicine, Humans, In patient, 030212 general & internal medicine, business.industry, Cholesterol, Anticholesteremic Agents, PCSK9, Absolute risk reduction, Antibodies, Monoclonal, Cholesterol, LDL, Evolocumab, chemistry, Cardiology, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, business, Cardiovascular outcomes
Abstract

We have read with great interest the results recently published by Bonaca et al1 regarding the effectiveness of evolocumab in patients with peripheral artery disease (PAD) from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). In their analysis, Bonaca et al1 report that evolocumab reduces the risk of major adverse cardiovascular events and major adverse limb events in patients with PAD, suggesting larger absolute risk reductions relative to those without. Moreover, in line with previous data reported in the literature,2, …

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results